Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 7238
Neuraminidase inhibitors work against influenza by preventing viruses from being released from infected cells and subsequently infecting further cells. Neuraminidase inhibitors are usually prescribed to patients presenting with flu-like symptoms during epidemic periods to reduce symptoms or prevent spread of the virus.
IPSCIO Record ID: 27998
InavirÂ® is a brand of laninamivir octanoate and also previously known as CS-8958. The approved indication is for the treatment of influenza in adults and children.
InavirÂ® (laninamivir octanoate), is the first drug of a new class of long acting neuraminidase inhibitors (LANIs) to address the limitation of the current products, which require daily or more frequent dosing. Neuraminidase inhibitors (NIs) are antiviral agents effective against influenza, providing both for the treatment of an established influenza infection or for the prevention of influenza prior to exposure.
IPSCIO Record ID: 856
Drugs that limit the multiplication of the influenza virus are generally only available by prescription from a doctor. This group comprises the drugs known as NIs, zanamivir (Relenzaâ„¢), laninamivir (InavirÂ®) and oseltamivir (TamifluÂ®) which act on both influenza A and B.
IPSCIO Record ID: 392
IPSCIO Record ID: 27993
The parties desire for Licensee to develop, manufacture, market, distribute and sell a product for treating or preventing influenza virus and/or infection, such as a vaccine comprising antigenic determinants of an influenza virus, like FluogenÂ®, which includes a proprietary adjuvant developed by Licensor.
IPSCIO Record ID: 1296
IPSCIO Record ID: 26110
Â· U.S. Patent No. 6,846,605 Inhibitors of serine protease activity, methods and compositions for the treatment of viral infections (related to Case # CU9014H).
Â· U.S. Patent Application No. 11/044,224 Inhibitors of serine protease activity, methods and compositions for the treatment of viral infections (Continuation application of Patent No. 6,846,605).
Â· Provisional Patent Application No. 60/742,191 Alpha-1-antitrypsin inhibition of disease and conditions mediated by binding to cell-associate actin (related to Case # CU1428H).
Â· Provisional Application No. 60/913,174 Title Compositions and Methods of Use for AlphaÂAnti Trypsin Having No Significant Serine Protease Inhibitor Activity (CU1697H US).
Â· PCT Application No, PCT/US2006/061577 Title Compositions and Methods For Treating Actin-Mediated Conditions (CU1428H).
Â· U.S. Patent Application No.11/719,200 Compositions and Methods For Treating Actin- Mediated Conditions (CU1428H US1).
Treatment of all viral infections including, without limitation, any and all mutations, strains, and subtypes, including future mutations, strains, and subtypes of Human Immunodeficiency Virus (HIV) (including any viral infections reasonably and/or previously withheld by the University, when they become available); Human Papilloma Virus (HPV); Herpes Simplex Virus (HSV); Hepacivirus; Pestivirus; Avian influenza virus; Human influenza virus; Murray Valley encephalitis; St. Louis encephalitis.